AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of success in costly clinical trials. Soriot said AstraZeneca is using AI tools and partnerships, including its work with Tempus AI and Pathos, to make smarter drug development decisions and accelerate innovation across its pipeline.